26469535 Visualization

A 73 Age - year Age - old Age woman Sex was initially referred Clinical_event 19 Date months Date prior to the current presentation, at which time fluorescein Detailed_description and indocyanine Detailed_description green Detailed_description angiography Diagnostic_procedure showed a medium Detailed_description - sized Detailed_description subfoveal Detailed_description classic Detailed_description CNV Disease_disorder in the left Biological_structure eye Biological_structure , which had not Detailed_description been Detailed_description previously Detailed_description treated Detailed_description .
She did not return for treatment Therapeutic_procedure until the current presentation, when she noted decreased Sign_symptom vision Sign_symptom in the left Biological_structure eye Biological_structure .
The best Diagnostic_procedure - corrected Diagnostic_procedure visual Diagnostic_procedure acuity Diagnostic_procedure ( BCVA Diagnostic_procedure ) was 20/100 Lab_value .
Slit Diagnostic_procedure lamp Diagnostic_procedure examination Diagnostic_procedure showed a small Detailed_description yellowish Color patch Sign_symptom in the perifoveal Biological_structure region Biological_structure and retinal Sign_symptom edema Sign_symptom .
Structural Detailed_description OCT Diagnostic_procedure revealed the retinal Sign_symptom elevation Sign_symptom , subretinal Sign_symptom fluid Sign_symptom and a hyper Biological_structure - reflective Biological_structure elongated Sign_symptom area Sign_symptom above Biological_structure RPE Biological_structure indicating type Lab_value II Lab_value CNV Disease_disorder .
Anti Therapeutic_procedure - angiogenic Therapeutic_procedure treatment Therapeutic_procedure with intravitreal Administration aflibercept Medication injections Administration were administered with a treat Detailed_description - and Detailed_description - extend Detailed_description regimen Detailed_description .
OCT Diagnostic_procedure angiograms Detailed_description (Fig.1) showed noticeable Lab_value reduction Lab_value in CNV Diagnostic_procedure flow Diagnostic_procedure area Diagnostic_procedure by 1–2 days Date post Date injection, with continued Lab_value reduction Lab_value at 1 Date week Date and Date 2 Date weeks Date .
CNV Diagnostic_procedure flow Diagnostic_procedure area Diagnostic_procedure and vessel Diagnostic_procedure density Diagnostic_procedure were reduced Lab_value , probably due to the decreased flow or temporary closure of the smaller anastomoses.
Significant Severity re Lab_value - appearance Lab_value of CNV Disease_disorder was noticeable at 4 Date weeks Date after the first injection and again at 6 Date weeks Date after the second injection.
The vascular pattern of the re Detailed_description - enlarged Detailed_description CNV Disease_disorder (Fig.1A) was very similar to the initial pretreatment CNV, suggesting that the recurrence may be reopening of original channels rather than growth of new vessels.
Comparing the CNV network prior to the 3rd injection to the baseline, it is notable that there were fewer smaller channels, while the larger caliber channels remained.
Quantitative measurements from OCT Diagnostic_procedure angiography Detailed_description (Fig.2A) showed reduction Lab_value in CNV Diagnostic_procedure flow Diagnostic_procedure area Diagnostic_procedure and flow Diagnostic_procedure index Diagnostic_procedure over Duration the Duration first Duration 2 Duration weeks Duration with subsequent return.
Retinal Sign_symptom thickness Sign_symptom (Fig.2B) showed the fluid resorption over Duration the Duration first Duration 4 Duration weeks Duration in the first treatment cycle continuing at least 2 Date weeks Date into the second treatment cycle, at which time no fluid remained (Fig.1B).
But fluid Sign_symptom re Sign_symptom - accumulated Sign_symptom under Biological_structure the Biological_structure retina Biological_structure 6 Date weeks Date after the 2nd injection.
Visual Diagnostic_procedure acuity Diagnostic_procedure (Fig.2B) continued Lab_value to Lab_value improve Lab_value over the 3 treatment cycles.